JP4658967B2 - 造血系起源の腫瘍の治療のための組成物と方法 - Google Patents

造血系起源の腫瘍の治療のための組成物と方法 Download PDF

Info

Publication number
JP4658967B2
JP4658967B2 JP2006547433A JP2006547433A JP4658967B2 JP 4658967 B2 JP4658967 B2 JP 4658967B2 JP 2006547433 A JP2006547433 A JP 2006547433A JP 2006547433 A JP2006547433 A JP 2006547433A JP 4658967 B2 JP4658967 B2 JP 4658967B2
Authority
JP
Japan
Prior art keywords
seq
antibody
taho
polypeptide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2006547433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007519632A5 (enExample
JP2007519632A (ja
Inventor
ウェスリー チャン，
ソーヴェージ， フレデリック デ
ダン， エル． イートン，
アレン， ジェイ． ジュニア． エベンス，
グレッチェン フランツ，
ジョ−アン エス． ホンゴー，
ハートムット ケッペン，
アンドリュー ポルソン，
ヴィクトリア スミス，
Original Assignee
ジェネンテック， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2004/038262 external-priority patent/WO2005049075A2/en
Priority claimed from US10/989,826 external-priority patent/US20050238650A1/en
Application filed by ジェネンテック， インコーポレイテッド filed Critical ジェネンテック， インコーポレイテッド
Publication of JP2007519632A publication Critical patent/JP2007519632A/ja
Publication of JP2007519632A5 publication Critical patent/JP2007519632A5/ja
Application granted granted Critical
Publication of JP4658967B2 publication Critical patent/JP4658967B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2006547433A 2003-12-24 2004-12-21 造血系起源の腫瘍の治療のための組成物と方法 Expired - Lifetime JP4658967B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US53242603P 2003-12-24 2003-12-24
PCT/US2004/038262 WO2005049075A2 (en) 2003-11-17 2004-11-16 Compositions and methods for the treatment of tumor of hematopoietic origin
US10/989,826 US20050238650A1 (en) 2002-04-17 2004-11-16 Compositions and methods for the treatment of tumor of hematopoietic origin
PCT/US2004/043514 WO2005063299A2 (en) 2003-12-24 2004-12-21 Compositions and methods for the treatment of tumor of hematopoietic origin

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010037990A Division JP2010154864A (ja) 2003-12-24 2010-02-23 造血系起源の腫瘍の治療のための組成物と方法
JP2010199100A Division JP2011019523A (ja) 2003-12-24 2010-09-06 造血系起源の腫瘍の治療のための組成物と方法

Publications (3)

Publication Number Publication Date
JP2007519632A JP2007519632A (ja) 2007-07-19
JP2007519632A5 JP2007519632A5 (enExample) 2010-04-15
JP4658967B2 true JP4658967B2 (ja) 2011-03-23

Family

ID=34743701

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006547433A Expired - Lifetime JP4658967B2 (ja) 2003-12-24 2004-12-21 造血系起源の腫瘍の治療のための組成物と方法
JP2010037990A Pending JP2010154864A (ja) 2003-12-24 2010-02-23 造血系起源の腫瘍の治療のための組成物と方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010037990A Pending JP2010154864A (ja) 2003-12-24 2010-02-23 造血系起源の腫瘍の治療のための組成物と方法

Country Status (6)

Country Link
US (1) US20080166294A1 (enExample)
EP (1) EP1696963A2 (enExample)
JP (2) JP4658967B2 (enExample)
AU (2) AU2004308972C1 (enExample)
CA (1) CA2551813C (enExample)
WO (1) WO2005063299A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7097840B2 (en) * 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
CA2480404A1 (en) 2002-03-25 2003-10-30 Uab Research Foundation Fc receptor homolog, reagents, and uses thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
AU2005216251B2 (en) * 2004-02-23 2011-03-10 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
WO2006039238A2 (en) * 2004-09-30 2006-04-13 The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Irta2 antibodies and methods of use
KR20070115881A (ko) * 2005-01-12 2007-12-06 메다렉스, 인코포레이티드 아이아르티에이-2 항체 및 그의 용도
MX2010005862A (es) * 2007-11-30 2010-11-30 Endo Pharmaceuticals Solutions Composiciones intravesicales con valrubicina para el tratamiento del cancer de vejiga.
US9879267B2 (en) * 2008-03-14 2018-01-30 Genentech, Inc. Genetic variations associated with drug resistance
HUE025507T2 (en) 2008-03-18 2016-02-29 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
RU2583270C2 (ru) 2009-04-01 2016-05-10 Дженентек, Инк. АНТИТЕЛА К FcRH5, ИХ ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
SG174992A1 (en) 2009-04-01 2011-11-28 Genentech Inc Anti-fcrh5 antibodies and immunoconjugates and methods of use
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
AU2012316859A1 (en) 2011-09-29 2014-04-17 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
EP2802356A1 (en) * 2012-01-13 2014-11-19 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
TWI725931B (zh) 2013-06-24 2021-05-01 美商建南德克公司 抗ｆｃｒｈ５抗體
KR102357961B1 (ko) 2013-12-17 2022-02-08 제넨테크, 인크. 항-cd3 항체 및 이의 사용 방법
US10323094B2 (en) 2015-06-16 2019-06-18 Genentech, Inc. Humanized and affinity matured antibodies to FcRH5 and methods of use
AU2023218150A1 (en) 2022-02-09 2024-08-29 Kyowa Kirin Co., Ltd. Antibody or fragment thereof that binds to fcrl1

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5686072A (en) * 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
JP2004522402A (ja) * 1999-06-02 2004-07-29 ジェネンテック・インコーポレーテッド 同一のものをコードする分泌及び膜貫通ポリペプチドと核酸
DE19926475A1 (de) * 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
HK1049843B (en) * 1999-11-29 2017-03-31 The Trustees Of Columbia University In The City Of New York Isolation of five novel genes coding for new fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
US20030078396A1 (en) * 2000-03-01 2003-04-24 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
WO2003097803A2 (en) * 2002-05-15 2003-11-27 Avalon Pharmaceuticals Cancer-linked gene as target for chemotherapy
CA2480404A1 (en) * 2002-03-25 2003-10-30 Uab Research Foundation Fc receptor homolog, reagents, and uses thereof
NZ596984A (en) * 2003-11-17 2013-10-25 Genentech Inc Compositions and methods for the treatment of tumor of hematopoietic origin

Also Published As

Publication number Publication date
AU2004308972B2 (en) 2009-05-28
AU2004308972C1 (en) 2009-11-26
CA2551813A1 (en) 2005-07-14
CA2551813C (en) 2014-08-12
JP2010154864A (ja) 2010-07-15
WO2005063299A2 (en) 2005-07-14
AU2009202783C1 (en) 2012-11-15
US20080166294A1 (en) 2008-07-10
AU2004308972A1 (en) 2005-07-14
AU2009202783B2 (en) 2012-05-03
EP1696963A2 (en) 2006-09-06
AU2009202783A1 (en) 2009-07-30
WO2005063299A3 (en) 2006-06-01
JP2007519632A (ja) 2007-07-19

Similar Documents

Publication Publication Date Title
JP5587841B2 (ja) 造血系起源の腫瘍の治療のための組成物と方法
JP4822710B2 (ja) 腫瘍の診断と治療のための組成物と方法
JP4912356B2 (ja) 腫瘍の診断及び治療のための組成物及び方法
JP4703567B2 (ja) 膠細胞起源の腫瘍の診断と治療のための組成物と方法
US20050238650A1 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
JP2010154864A (ja) 造血系起源の腫瘍の治療のための組成物と方法
JP2010154864A6 (ja) 造血系起源の腫瘍の治療のための組成物と方法
US20110045005A1 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
JP2005536190A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006510735A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006516089A (ja) 腫瘍の診断と治療のための組成物と方法
JP2005536439A (ja) 腫瘍の診断及び治療のための組成物と方法
JP2008137989A (ja) 腫瘍の診断と治療のための組成物と方法
JP2007519632A5 (enExample)
US7754441B2 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
US20070207142A1 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
JP2007521791A (ja) 腫瘍の診断と治療のための組成物と方法
US7888478B2 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
US20050226869A1 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
US7858330B2 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
JP2006104212A (ja) 腫瘍の診断と治療のための組成物と方法
JP2006516655A (ja) 腫瘍の診断と治療のための組成物と方法
JP2007512019A (ja) 腫瘍の診断と治療のための組成物と方法
US20060002943A1 (en) Compositions and methods for the treatment of tumor of hematopoietic origin
JP2011019523A (ja) 造血系起源の腫瘍の治療のための組成物と方法

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091027

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100203

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100705

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100712

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100806

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100813

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100906

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20101130

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20101224

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140107

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4658967

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term